ABX Stock Analysis: Abacus Global Management | NYSE

Insurance - Life | NYSE, USA | Market Cap: 953m USD | 12M Return: 51.9% | US00258Y1047 | Charts, Fundamentals & Technical Analysis

Asset Management, Life Settlements, Mortality Verification, Alternative Investments
Total Rating 48
Safety 57
Buy Signal -0.57
Insurance - Life
Industry Rotation: -7.6
Market Cap: 953M
Avg Turnover: 4.84M
Risk 3d forecast
Volatility56.7%
VaR 5th Pctl8.74%
VaR vs Median-5.13%
Reward TTM
Sharpe Ratio0.92
Rel. Str. IBD73.7
Rel. Str. Peer Group55
Character TTM
Beta0.481
Beta Downside-0.084
Hurst Exponent0.543
Drawdowns 3y
Max DD62.79%
CAGR/Max DD0.14
CAGR/Mean DD0.31
EPS (Earnings per Share) EPS (Earnings per Share) of ABX over the last years for every Quarter: "2021-09": 0.2496, "2021-12": 0.25, "2022-03": 0.03, "2022-06": 0.22, "2022-09": -0.26, "2022-12": -0.1388, "2023-03": -0.14, "2023-06": 0.1336, "2023-09": 0.0143, "2023-12": -0.0984, "2024-03": -0.0214, "2024-06": 0.18, "2024-09": 0.2, "2024-12": -0.22, "2025-03": 0.18, "2025-06": 0.22, "2025-09": 0.2, "2025-12": 0.23, "2026-03": 0.2, "2026-06": 0.28,
Last SUE: 0.20
Qual. Beats: 0
Revenue Revenue of ABX over the last years for every Quarter: 2021-09: 0.321822, 2021-12: 0.321822, 2022-03: 0.203404, 2022-06: 5.691916, 2022-09: 11.507748, 2022-12: -4.580585, 2023-03: 10.273389, 2023-06: 11.378765, 2023-09: 21.12093, 2023-12: 23.695547, 2024-03: 21.487184, 2024-06: 29.076102, 2024-09: 28.148491, 2024-12: 33.212009, 2025-03: 44.139346, 2025-06: 56.22462, 2025-09: 62.975156, 2025-12: 71.898514, 2026-03: 59.390288, 2026-06: 73.01999,
Rev. CAGR: 91.00%
Rev. Trend: 98.0%
Qual. Beats: 0

Warnings

Choppy

Tailwinds

No distinct edge detected

Seasonality 5.9 years of data

Jan +0.0% 9
Feb +0.0% 9
Mar +0.1% 9
Apr +0.1% 24
May -2.5% 46
Jun -2.7% 10
Jul +0.5% 9
Aug +19.4% 23
Sep -1.9% 11
Oct -8.7% 47
Nov +0.3% 23
Dec +0.4% 10

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: ABX Abacus Global Management

Abacus Global Management, Inc. (NYSE: ABX) is a U.S.-based alternative asset manager and market maker that operates across three business segments: Asset Management, Life Solutions, and Technology Services. Founded in 2004 and headquartered in Orlando, Florida, the company distributes its offerings through financial advisors, direct-to-consumer channels, and traditional life settlements intermediaries, with operations in the United States, Luxembourg, and other international markets. The firm rebranded from Abacus Life, Inc. to its current name in February 2025 to reflect its broader alternative asset management focus beyond its original life insurance roots.

The Life Solutions segment is the companys core business, acting as an intermediary that connects buyers and sellers in the life settlements market, where existing life insurance policies are sold by original owners to third-party investors. The Asset Management segment manages investments in alternative investment vehicles and exchange-traded funds on behalf of clients, while the Technology Services segment provides contract-based solutions such as real-time mortality verification and missing participant verification, which are specialized back-office services used by insurers, pension funds, and other participants in the life insurance market.

ABX is classified within the Financials sector under the Insurance Brokers sub-industry and trades as a small-cap stock with a market capitalization around $927 million. Its three-segment structure-combining origination of life insurance policy settlements, asset management, and related technology infrastructure-positions it as a vertically integrated participant in the alternative investments and life insurance services space.

Headlines to Watch Out For
  • Life settlement origination volume expands across operating segments
  • Interest rate shifts impact policy valuation and investment yields
  • Asset Management AUM growth drives recurring fee revenue
Piotroski VR-10 (Strict) 4.5
Net Income: 28.2m TTM > 0 and > 6% of Revenue
FCF/TA: 0.10 > 0.02 and ΔFCF/TA 25.64 > 1.0
NWC/Revenue: 12.30% < 20% (prev -21.18%; Δ 33.48% < -1%)
CFO/TA 0.10 > 3% & CFO 90.8m > Net Income 28.2m
Net Debt (332.2m) to EBITDA (101.1m): 3.29 < 3
Current Ratio: 1.77 > 1.5 & < 3
Outstanding Shares: last quarter (99.8m) vs 12m ago 2.45% < -2%
Gross Margin: 68.55% > 18% (prev 88.21%; Δ -19.66% > 0.5%)
Asset Turnover: 31.15% > 50% (prev 19.06%; Δ 12.09% > 0%)
Interest Coverage Ratio: 2.16 > 6 (EBIT TTM 84.6m / Interest Expense TTM 39.2m)
Altman Z'' 1.88
A: 0.04 (Total Current Assets 75.3m - Total Current Liabilities 42.4m) / Total Assets 867.7m
B: -0.03 (Retained Earnings -27.9m / Total Assets 867.7m)
C: 0.10 (EBIT TTM 84.6m / Avg Total Assets 858.0m)
D: 1.03 (Book Value of Equity 439.7m / Total Liabilities 428.1m)
Altman-Z'' = 1.88 = BBB
Beneish M -2.09
DSRI: 1.22 (Receivables 51.9m/25.6m, Revenue 267.3m/161.7m)
GMI: 1.29 (GM 88.21% / 68.55%)
AQI: 1.04 (AQ_t 0.91 / AQ_t-1 0.87)
SGI: 1.65 (Revenue 267.3m / 161.7m)
TATA: -0.07 (NI 28.2m - CFO 90.8m) / TA 867.7m)
Beneish M = -2.09 (Cap -4..+1) = BB
What is the price of ABX shares?

As of September 05, 2026, the stock is trading at USD 9.61 with a total of 313,867 shares traded. Over the past week, the price has changed by -1.33%, over one month by -11.51%, over three months by +8.34% and over the past year by +51.92%.

Current recommended Stop Loss: 8.50 (which is 11.6% or 2.6 ATR below the current price).

Is ABX a buy, sell or hold?

Abacus Global Management has no consensus analysts rating.

Abacus Global Management (ABX) - Fundamental Data Overview as of 30 August 2026
Market Cap USD = 952.5m (952.5m USD * 1.0 USD.USD)
P/E Trailing = 36.0741
P/E Forward = 10.5708
P/S = 3.5636
P/B = 2.2115
Revenue TTM = 267.3m USD
EBIT TTM = 84.6m USD
EBITDA TTM = 101.1m USD
Long Term Debt = 289.9m USD (from longTermDebt, last fiscal year)
Short Term Debt = 42.4m USD (from shortTermDebt, last quarter)
Debt = 355.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 11.3m
Net Debt = 332.2m USD (calculated: Debt 355.6m - CCE 23.4m)
Enterprise Value = 1.28b USD (952.5m + Debt 355.6m - CCE 23.4m)
Interest Coverage Ratio = 2.16 (Ebit TTM 84.6m / Interest Expense TTM 39.2m)
EV/FCF = 14.48x (Enterprise Value 1.28b / FCF TTM 88.7m)
FCF Yield = 6.91% (FCF TTM 88.7m / Enterprise Value 1.28b)
FCF Margin = 33.20% (FCF TTM 88.7m / Revenue TTM 267.3m)
Net Margin = 10.55% (Net Income TTM 28.2m / Revenue TTM 267.3m)
Gross Margin = 68.55% ((Revenue TTM 267.3m - Cost of Revenue TTM 84.1m) / Revenue TTM)
Gross Margin QoQ = 76.73% (prev 76.13%)
Tobins Q-Ratio = 1.48 (Enterprise Value 1.28b / Total Assets 867.7m)
Interest Expense / Debt = 11.02% (Interest Expense 39.2m / Debt 355.6m)
Taxrate = 37.85% (17.2m / 45.4m)
NOPAT = 52.6m (EBIT 84.6m * (1 - 37.85%))
Current Ratio = 1.77 (Total Current Assets 75.3m / Total Current Liabilities 42.4m)
Debt / Equity = 0.81 (Debt 355.6m / totalStockholderEquity, last quarter 439.7m)
Debt / EBITDA = 3.29 (Net Debt 332.2m / EBITDA 101.1m)
Debt / FCF = 3.74 (Net Debt 332.2m / FCF TTM 88.7m)
Total Stockholder Equity = 430.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.29% (Net Income 28.2m / Total Assets 867.7m)
RoE = 6.56% (Net Income TTM 28.2m / Total Stockholder Equity 430.1m)
RoCE = 11.74% (EBIT 84.6m / Capital Employed (Equity 430.1m + L.T.Debt 289.9m))
RoIC = 6.15% (NOPAT 52.6m / Invested Capital 854.4m)
WACC = 7.45% (E(952.5m)/V(1.31b) * Re(7.67%) + D(355.6m)/V(1.31b) * Rd(11.02%) * (1-Tc(0.38)))
Discount Rate = 7.67% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 90.99 | Cagr: 22.64%
[DCF] Terminal Value 75.44% ; FCFF base≈88.7m ; Y1≈89.1m ; Y5≈94.4m
[DCF] Fair Price = 11.61 (EV 1.47b - Net Debt 332.2m = Equity 1.14b / Shares 97.8m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.20 | # QB: 0
Revenue Correlation: 98.05 | Revenue CAGR: 91.00% | SUE: N/A | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.26 | Chg30d=-3.20% | Revisions=-25% | Analysts=6
EPS current Year (2026-12-31): EPS=1.02 | Chg30d=+0.00% | Revisions=+40% | GrowthEPS=+18.6% | GrowthRev=+21.9%
EPS next Year (2027-12-31): EPS=1.15 | Chg30d=+1.38% | Revisions=+25% | GrowthEPS=+12.9% | GrowthRev=+17.8%
[Analyst] Revisions Ratio: +29% (up=3, down=1)